| Description | 1V209 (TLR7 agonist T7) is a Toll-like receptor 7 (TLR7) agonist and has anti-tumor effects. |
| In vitro | The small molecule synthetic TLR7 ligand, 2-methoxyethoxy-8-oxo-9-(4-carboxy benzyl)adenine (1V209), and α-mannose were coimmobilized via linker molecules consisting of thioctic acid on the GNP surface (1V209-αMan-GNPs).?The in vitro cytokine production activity of 1V209-αMan-GNPs was higher than that of the unconjugated 1V209 derivative in mouse bone marrow-derived dendritic cells and in human peripheral blood mononuclear cells[1]. |
| In vivo | In the in vivo immunization study, 1V209-αMan-GNPs induced significantly higher titers of IgG2c antibody specific to ovalbumin as an antigen than did unconjugated 1V209, and splenomegaly and weight loss were not observed[1]. |
| Synonyms | TLR7 agonist T7 |
| molecular weight | 359.34 |
| Molecular formula | C16H17N5O5 |
| CAS | 1062444-54-5 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 83.33 mg/mL (231.90 mM), Sonication is recommended. |
| References | 1. Gold Nanoparticles Coimmobilized with Small Molecule Toll-Like Receptor 7 Ligand and α‑Mannose as Adjuvants[J]. Bioconjugate Chemistry, 2019, 30(11):2811-2821. 2. Shinchi H, et al. Enhancement of the Immunostimulatory Activity of a TLR7 Ligand by Conjugation to Polysaccharides. Bioconjug Chem. 2015 Aug 19;26(8):1713-23. 3. Battistella C, et al. Delivery of Immunotherapeutic Nanoparticles to Tumors via Enzyme-Directed Assembly. Adv Healthc Mater. 2019 Dec;8(23):e1901105. |
| Citations | 1. Liang C, Xiong N, Liu M, et al.Manganese immunotherapy for treating osteosarcoma: Glycosylating 1V209 anchored MnO2 nanosheets prompt pro-inflammatory macrophage polarization.Nano Today.2023, 48: 101670. |